RecruitingPrimary Biliary Cholangitis (PBC)
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study
Eligible age
18–75 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination with Ursodeoxycholic Acid in Subjects with Primary Biliary Cholangitis (PBC)
Sponsor: Xijing Hospital of Digestive Diseases
You may qualify if…
- ✓ 1. Must have given written informed consent (signed and dated)
- ✓ 2. Completed in a PBC study with fenofibrate(NCT05751967)
- ✓ 3. Females of reproductive potential must use at least one barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male subjects who are sexually active with female partners of reproductive potential must use barrier contraception and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose
You may not qualify if…
- ✕ 1. Treatment-related adverse event (AE) leading to study drug discontinuation in a previous PBC study with seladelpar
- ✕ 2. A medical condition, other than PBC, that in the Investigator's opinion would preclude full participation in the study or confound its results
Source: ClinicalTrials.gov · NCT06755541 · last updated 2026-01-08